Pacira BioSciences (NASDAQ: PCRX) has recently received a number of price target changes and ratings updates:
- 9/1/2026 – Pacira BioSciences was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
- 8/17/2026 – Pacira BioSciences had its “sell (d+)” rating reaffirmed by Weiss Ratings.
- 8/17/2026 – Pacira BioSciences is now covered by Truist Financial Corporation. They set a “buy” rating and a $30.00 price target on the stock.
- 8/16/2026 – Pacira BioSciences was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 8/8/2026 – Pacira BioSciences was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 8/5/2026 – Pacira BioSciences had its price target raised by Royal Bank Of Canada from $24.00 to $25.00. They now have a “sector perform” rating on the stock.
- 8/5/2026 – Pacira BioSciences had its price target raised by Needham & Company LLC from $32.00 to $33.00. They now have a “buy” rating on the stock.
Insider Transactions at Pacira BioSciences
In related news, SVP Lauren Riker sold 6,115 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total value of $143,702.50. Following the sale, the senior vice president directly owned 62,284 shares in the company, valued at $1,463,674. This represents a 8.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,040 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $23.23, for a total transaction of $70,619.20. Following the sale, the insider directly owned 216,384 shares of the company’s stock, valued at $5,026,600.32. This represents a 1.39% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.40% of the company’s stock.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Recommended Stories
- Five stocks we like better than Pacira BioSciences
- SLB’s Kelvion Deal Could Change How Investors Value the Oilfield Giant
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
Receive News & Ratings for Pacira BioSciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.
